首页> 美国卫生研究院文献>other >Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach
【2h】

Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach

机译:走向个性化的基于肽的癌症纳米疫苗:一种简便通用的合成方法。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Personalized cancer vaccines (PCVs) are receiving attention as an avenue for cancer immunotherapy. PCVs employ immunogenic peptide epitopes capable of stimulating the immune system to destroy cancer cells with great specificity. Challenges associated with effective delivery of these peptides include poor solubility of hydrophobic sequences, rapid clearance, and poor immunogenicity, among others. The incorporation of peptides into nanoparticles has the potential to overcome these challenges, but the broad range of functionalities found in amino acids presents a challenge to conjugation due to possible interferences and lack of reaction specificity. Herein, a facile and versatile approach to generating nanosized PCVs under mild nonstringent conditions is reported. Following a simple two-step semibatch synthetic approach, amphiphilic hyperbranched polymer–peptide conjugates were prepared by the conjugation of melanoma antigen peptides, either TRP2 (hydrophobic) or MUT30 (hydrophilic), to an alkyne functionalized core via strain-promoted azide–alkyne click chemistry. Self-assembly of the amphiphiles gave spherical nanovaccines (by transmission electron microscopy) with sizes in the range of 10–30 nm (by dynamic light scattering). Fluorescently labeled nanovaccines were prepared to investigate the cellular uptake by antigen presenting cells (dendritic cells), and uptake was confirmed by flow cytometry and microscopy. The TRP2 nanovaccine was taken up the most followed by MUT30 nanoparticles and, finally, nanoparticles without peptide. The nanovaccines showed good biocompatibility against B16–F10 cells, yet the TRP2 peptide showed signs of toxicity, possibly due to its hydrophobicity. A test for immunogenicity revealed that the nanovaccines were poorly immunogenic, implying the need for an adjuvant when administered in vivo. Treatment of mice with melanoma tumors showed that in combination with adjuvant, CpG, groups with the peptide nanovaccines slowed tumor growth and improved survival (up to 24 days, TRP2) compared to the untreated group (14 days).
机译:个性化癌症疫苗(PCV)作为癌症免疫疗法的一种途径正受到关注。 PCV采用能够刺激免疫系统以高度特异性破坏癌细胞的免疫原性肽表位。与这些肽的有效递送相关的挑战包括疏水序列的溶解性差,快速清除和免疫原性差等。将肽掺入纳米颗粒具有克服这些挑战的潜力,但是由于可能的干扰和缺乏反应特异性,氨基酸中发现的广泛功能性对缀合提出了挑战。本文中,报道了在温和的非严格条件下产生纳米级PCV的简便且通用的方法。通过简单的两步半分批合成方法,通过应变促进的叠氮化物-炔烃偶联,将黑色素瘤抗原肽(疏水性)或MUT30(亲水性)偶联至炔烃官能化核心,从而制备两亲性超支化聚合物-肽偶联物化学。两亲物的自组装产生球形纳米疫苗(通过透射电子显微镜),大小在10–30 nm范围内(通过动态光散射)。制备荧光标记的纳米疫苗以研究抗原呈递细胞(树突状细胞)对细胞的摄取,并通过流式细胞仪和显微镜检查确认摄取。摄取最多的是TRP2纳米疫苗,其次是MUT30纳米颗粒,最后是不含肽的纳米颗粒。纳米疫苗对B16–F10细胞显示出良好的生物相容性,而TRP2肽则显示出毒性迹象,可能是由于其疏水性所致。免疫原性测试表明,纳米疫苗的免疫原性较差,这意味着在体内给药时需要佐剂。黑色素瘤肿瘤小鼠的治疗显示,与未治疗的组(14天)相比,与肽CpG佐剂联合的组,纳米肽疫苗减慢了肿瘤的生长,提高了存活率(长达24天,TRP2)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号